Golden Biotechnology Corporation (TPEX:4132)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
3.470
0.00 (0.00%)
Apr 9, 2026, 2:59 PM CST
Market Cap562.93M -77.5%
Revenue (ttm)44.58M -22.5%
Net Income-314.93M
EPS-1.96
Shares Out162.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,061,471
Average Volume5,360,770
Open4.850
Previous Close3.470
Day's Range3.470 - 5.090
52-Week Range3.470 - 36.300
Beta1.08
RSI21.18
Earnings DateApr 27, 2026

About Golden Biotechnology

Golden Biotechnology Corporation engages in research and development of new drug in Taiwan. The company offers Antroquinonol for the treatment of pancreatic cancer, acute myeloid leukemia, blood diseases, non-small cell lung cancer, COVID-19, and other diseases. It is also involved in development and sale of health foods and supplements, as well as provides products for oncology, infectious, and neurodegenerative diseases. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan. [Read more]

Sector Healthcare
Founded 2002
Employees 116
Stock Exchange Taipei Exchange
Ticker Symbol 4132
Full Company Profile

Financial Performance

In 2024, Golden Biotechnology's revenue was 40.92 million, a decrease of -35.49% compared to the previous year's 63.43 million. Losses were -360.70 million, -0.26% less than in 2023.

Financial Statements